Table 3.

CA15.3 and CEA distribution in patients with disease progression after achieving a complete/partial response or stable disease (n=47).

Measurement time	Marker: CA15.3	p value	Marker: CEA	p value
Pretreatment	74 (31.56–168)	<0.001* (global difference)	6.7 (2.1–21.05)	<0.001* (global difference)
Best response	61 (28.4–150.05)		4.4 (1.73–22.15)
Progression disease	95 (47–270)		6.8 (2.95–32.1)
Change	Marker: CA15.3	p value	Marker: CEA	p value
Between PT and BR	−3.5 (−52.5 to 13.33)	0.113	−0.3 (−6.24 to 0.47)	0.110
Between BR and PD	29 (5.5–106.3)	<0.001*	1.9 (0.28–7.95)	<0.001*
Between PT and PD	10.7 (−9.35 to 67.5)	0.031*	0.9 (−0.7 to 4.87)	0.066

Tumour marker distribution and change between measurement times are described in terms of median value (interquartile range). p values from analysis of biomarker change are derived from the two-sided one-sample Wilcoxon signed rank test. p values for global differences between time are derived from the Friedman test.

^*p<0.05.

BR, best response; PD, progressive disease; PT, pretreatment.